Q32 Bio Inc. (QTTB) AI Stock Analysis

Q32 Bio Inc., based in Waltham, Massachusetts, is a clinical-stage biotechnology company focused on developing biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases. Its pipeline includes ADX-097, a humanized anti-C3d monoclonal antibody fusion protein engineered to restore complement regulation, which completed Phase I trials for renal and complement-mediated diseases like lupus nephritis. It is also developing Bempikibart (ADX-914), a fully human monoclonal antibody that antagonizes the interleukin-7 receptor alpha, currently in Phase II trials for atopic dermatitis and alopecia areata. Formerly known as AdMIRx Inc., the company rebranded in April 2020.

Revenue reached $53.7M in FY2025, up from -$6.7M in FY2023, $6.7M in FY2022, and $34.0M in FY2021. The 5-year revenue CAGR from FY2019 to FY2025 was 100.3%. In FY2025, gross margin stood at 100.0%, operating margin was 31.5%, and net income turned positive to $29.8M, compared to net income of -$53.7M in FY2023 and -$42.8M in FY2022. FY2025 diluted EPS was $2.30. For the trailing twelve months ended June 30, 2026, revenue stood at $53.7M, operating margin was 39.9%, and profit margin reached 62.9%, with an EPS of $3.15.

As of June 30, 2026, Q32 Bio held $106.3M in cash and short-term investments against $5.3M in total debt, yielding net cash of $101.0M. Total assets stood at $115.9M and shareholders' equity was $105.9M. Liquidity was supported by a current ratio of 20.30 and a debt-to-equity ratio of 0.05. In FY2025, operating cash flow was -$33.5M, free cash flow was -$33.5M, and capital expenditures were $2,000. Over five years, the share count grew 343.9%.

At its last close of $7.52 on October 16, 2026, Q32 Bio had a market capitalization of $223.9M and an enterprise value of $183.2M. The stock traded at a trailing P/E of 2.4x, well below the median of its US-listed Healthcare peers of 24.6x. Its EV/EBITDA of 5.1x also sat below the peer median of 12.0x, while its price-to-sales of 4.2x was near the peer median of 4.1x. Over the past year, Q32 Bio returned 108.9%, outperforming the S&P 500 (SPY) return of 16.8%, though its 5-year return of -93.3% lagged SPY's 83.0% gain.

Wall Street analysts hold 6 Strong Buy ratings and 1 Buy rating on Q32 Bio, with zero Hold, Sell, or Strong Sell recommendations. The mean price target is $39.67, representing a 427.5% premium over the last close of $7.52. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $333,330 and EPS of -$1.50. For the following fiscal year, seven analysts project revenue of $833,330 and EPS of -$2.27. Q32 Bio beat EPS estimates in all 4 of its last four quarters, with its next earnings date scheduled for November 12, 2026.

This page is an AI-written research summary of Q32 Bio Inc. (QTTB). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: QTTB income statement, QTTB balance sheet, QTTB key metrics, QTTB analyst forecast, QTTB chart. See the QTTB stock overview for the latest quote and news.